SENIOR INVESTIGATORS

Dr. Elliott AntmanElliott Antman, MD is Professor of Medicine and Associate Dean for Clinical/Translational Research at Harvard Medical School, a Senior Investigator in the Thrombolysis in Myocardial Infarction (TIMI) Study Group, a Senior Physician in the Cardiovascular Division of the Brigham and Women's Hospital in Boston, Massachusetts. He was President of the American Heart Association (2014-2015).  The American Heart Association honored him with the 2016 Paul Dudley White Award.

As a Senior Investigator in the TIMI Study Group, he has published on the use of serum cardiac markers for diagnosis and prognosis of patients with unstable angina and acute myocardial infarction, cyclooxygenase and cardiovascular risk, and antithrombotic therapy for acute coronary syndromes.  His ongoing research studies help refine diagnostic and therapeutic modalities in routine clinical use today including cardiac specific troponins and novel antithrombotic agents.

At Brigham and Women’s Hospital, Dr. Antman has been recognized for his active role and interest in education and training. He is the recipient of many awards from the housestaff and has been honored for his contributions by the Harvard Medical School when it awarded him the A. Clifford Barger Excellence in Mentoring Award. Dr. Antman is Director of the Skills Development Center of the Boston Biomedical Innovation Center at the Brigham and Women’s Hospital.

Dr. Antman is the Director of the Harvard Catalyst Program for Education in Clinical and Translational Science. The goal of this program is to establish the infrastructure for coordination, integration, and oversight of clinical/translational postgraduate educational and training opportunities throughout the entire Harvard University system. 

Dr. Antman participates actively in American Heart Association (AHA) and American College of Cardiology (ACC) activities, locally, nationally, and internationally. He was the Chairman of the joint ACC/AHA Task Force on Practice Guidelines from January 2003 through December 2005. From 2011-12, Dr. Antman chaired the AHA’s Committee on Scientific Sessions Programs and introduced the AHA’s Emerging Science Webinar Series. Dr. Antman was on the AHA’s National Board of Directors, chaired the AHA Science and Advisory Coordinating Committee, chaired the AHA Advocacy Coordinating Committee, and chaired the AHA Manuscript Oversight Committee. He is chair of the AHA International Science and Programs Subcommittee of the International Committee. He is the recipient of the Meritorious Achievement Award from the AHA and is the recipient of the James B. Herrick Award for Outstanding Achievement in Clinical Cardiology (Council on Clinical Cardiology).

Dr. Antman is married to Dr. Karen Antman, who is the Dean of Boston University School of Medicine and Provost of the Boston University Medical Center.

Christopher P. Cannon, MDChristopher P. Cannon, MD has served a senior investigator in the Thrombolysis in Myocardial Infarction (TIMI) Study Group, leading trials such as TACTICS-TIMI 18, PROVE IT-TIMI 22, and CLARITY-TIMI 28. He currently is the principal investigator for the IMPROVE IT, SOLID-TIMI 52 and North American PI for the REVEAL- HPS3-TIMI 55 trial.

He earned his MD from Columbia University College of Physicians and Surgeons in New York, and after completing his residency in internal medicine at Columbia Presbyterian Medical Center, he was a cardiovascular fellow at Brigham and Women's Hospital.

Dr. Cannon has published over 1000 original articles, reviews, or electronic publications in the field of acute coronary syndromes and prevention and has authored or edited 17 books. He has served as editor-in-chief of the Science and Quality section of American College of Cardiology's website, www.Cardiosource.org. He has received numerous awards, including leadership awards from the American College of Cardiology and the American Heart Association.

Robert P. Giugliano, MDRobert P. Giugliano, MD, SM is a Senior Investigator with the Thrombolysis in Myocardial Infarction (TIMI) Study Group, Staff Physician in the Cardiovascular Division at the Brigham and Women’s Hospital and Associate Professor of Medicine at Harvard Medical School. He graduated summa cum laude and phi beta kappa, and received his medical degree at Harvard Medical School. Dr. Giugliano completed his internship, residency, and chief residency at Cedars-Sinai Medical Center, Los Angeles and then returned to Boston as a Cardiology Fellow at the Massachusetts General Hospital.

Dr. Giugliano joined the Brigham and Women’s Hospital in 1996, worked with the TIMI Study Group, and completed a Master of Science degree in epidemiology at the Harvard School of Public Health and joined the Cardiovascular Division in 1997.

His research interests include novel antithrombotic therapies for atrial fibrillation and acute coronary syndromes (ACS), lipid-lowering therapies and the assessment of outcomes in patients with ACS. Dr. Giugliano has authored more than 250 original articles and 150 reviews/editorials/book chapters. He is the Founding Scientific Advisor and Editor-in-Chief for MD Conference Express, Co-Editor-in-Chief of Cardiology and Therapy, and serves on editorial boards for Circulation, The American Heart Journal, Clinical Cardiology, Cor et Vasa, Hospital Practice, Cardiovascular Therapeutics and Clinical Pathways in Cardiology.

Dr. Giugliano is the Principal TIMI Investigator for the ENGAGE AF-TIMI 48, LAPLACE-TIMI 57 and EARLY ACS trials, ANTHEM-TIMI 32 and Executive Committee member of the IMPROVE-IT. FOURIER, and EBBINGHAUS trials.

David A. Morrow, MD, MPHDavid A. Morrow, MD, MPH is the Director of the Samuel A. Levine Cardiac Intensive Care Unit in the Division of Cardiovascular Medicine at Brigham and Women's Hospital and a Professor of Medicine at Harvard Medical School. Dr. Morrow earned his medical degree from Harvard Medical School and a Masters in Public Health with a concentration in clinical study design and interpretation from the Harvard School of Public Health. He completed his medical residency in Internal Medicine and fellowship in Cardiovascular Medicine at Brigham and Women's Hospital.

Dr. Morrow is a Senior Investigator in the Thrombolysis in Myocardial Infarction Study Group at Brigham and Women's Hospital with a research focus in the management of unstable and stable coronary artery disease. He also directs the TIMI Biomarker Program.

Dr. Morrow is an internationally recognized expert in risk stratification in patients with ischemic heart disease. He has served on the National Academy of Clinical Biochemistry (NACB) Laboratory Medicine Practice Guidelines Committee on Biochemical Cardiac Markers for which he led the clinical section on acute coronary syndromes, and on the Program Committee for the American Heart Association Council on Clinical Cardiology. He is a member of the Global Task Force for a Universal Definition of Myocardial Infarction and of the American College of Cardiology/American Heart Association Guidelines Committee for Management of ST-elevation Myocardial Infarction. He sits on the editorial boards of the American Heart Journal, Circulation, Clinical Chemistry, European Heart Journal: Acute Cardiovascular Care, and the Journal of the American College of Cardiology. He has been a special section Co-Editor for Continuing Medical Education at Circulation. Dr. Morrow has more than 150 original scientific reports, reviews, editorials, book chapters and electronic publications in his areas of expertise, and is the editor of Cardiovascular Biomarkers, a text on application of biomarkers in Cardiovascular disease.

Deepak L. Bhatt MD, MPHDeepak L. Bhatt MD, MPH is Executive Director of Interventional Cardiovascular Programs at Brigham and Women's Hospital Heart & Vascular Center and Professor of Medicine at Harvard Medical School. He is also a Senior Physician at Brigham and Women's Hospital and a Senior Investigator in the TIMI Study Group.

After graduating as valedictorian from the Boston Latin School, Dr. Bhatt obtained his undergraduate science degree as a National Merit Scholar at the Massachusetts Institute of Technology while also serving as a research associate at Harvard Medical School. He received his medical doctorate from Cornell University. He completed a Masters in Public Health at Harvard University. His internship and residency in internal medicine were performed at the Hospital of the University of Pennsylvania, and his cardiovascular training was at Cleveland Clinic. He also completed fellowships in interventional cardiology and cerebral and peripheral vascular intervention as well as serving as Chief Interventional Fellow at Cleveland Clinic where he spent several years as an interventional cardiologist and an Associate Professor of Medicine. He served for many years as Director of the Interventional Cardiology Fellowship and as Associate Director of the Cardiovascular Medicine Fellowship. He also served as Associate Director of the Cleveland Clinic Cardiovascular Coordinating Center. He was then recruited to be the Chief of Cardiology at VA Boston Healthcare System where he served for several years.

Dr. Bhatt has authored or co-authored over 900 publications. He was the international PI for the CHARISMA and CRESCENDO trials and co-PI of the three CHAMPION trials. He served as chair of COGENT and helped lead STAMPEDE. He serves as co-chair of the REACH registry. He is also co-PI of SAVOR-TIMI 53 and SYMPLICITY HTN-3. He is the current Chair of the AHA-GWTG Steering Committee. He is Senior Associate Editor for clinical trials for the ACC's Cardiosource. He is the Editor-in-Chief of the Harvard Heart Letter. He is the Editor of Cardiovascular Intervention: A Companion to Braunwald’s Heart Disease.

Stephen D. Wiviott, MD, FACCStephen D. Wiviott, MD, FACC is a graduate of University of Pennsylvania (Mathematics, Magna Cum Laude) and Harvard Medical School (Honors). He served as a Medical House Officer and Chief Medical Resident at Brigham and Women's Hospital. Following his medical residency training, he served as a Cardiology Fellow at Johns Hopkins Hospital and as a Cardiovascular Research Fellow with the TIMI Study Group with the Cardiovascular Division of Brigham and Women's Hospital. After completion of his training he has joined the faculty of the Cardiovascular Division of Brigham and Women's Hospital and serves as Associate Professor of Medicine at Harvard Medical School, as well as a Senior Investigator with the Thrombolysis in Myocardial Infarction (TIMI) Study Group. He attends in the Lown Cardiovascular Intensive Care Unit at BWH.

 As a Senior Investigator with the TIMI Study Group, Dr. Wiviott has played important roles in the planning, implementation, and interpretation of several multicenter, national, and international clinical trials in acute coronary syndromes and those studying antiplatelet therapies. He has played leadership roles in the JUMBO-TIMI 26 trial and the TRITON-TIMI 38 trial, the major phase II and III trials which led to the approval of prasugrel. He was the Principal Investigator (PI) of PRINCIPLE-TIMI 44, a study comparing high-dose clopidogrel with prasugrel in patients undergoing PCI, and of the TIMI 38 Coronary Stent Registry. He has also served key roles in trials of secondary prevention of Cardiovascular Disease as an executive committee member of REVEAL, and co-PI of DECLARE – TIMI 58 and CAMELLIA – TIMI 61 assessing Cardiovascular Safety and Efficacy of metabolic therapies.  He is the Chairman of the TIMI Clinical Events Committee, and an expert in clinical event definitions and adjudications.

Dr. Wiviott is an author of more than 150 peer-reviewed publications in major medical and cardiovascular journals and of multiple chapters in major cardiovascular textbooks, including Braunwald's Heart Disease and Cardiovascular Therapeutics, a companion to Braunwald's Heart Disease. He was named in 2014 by Thomson Reuters as one of “The World’s Most Influential Scientific Minds” and in 2016 as a “Highly Cited Researcher,” inclusive of the top 1% of researchers in Clinical Medicine.  He has delivered local, national, and international lectures in the field of acute coronary syndromes, platelet biology, established and novel antiplatelet agents, diabetes and prevention. Areas of clinical and research interest include acute coronary syndromes, platelet inhibitors, cholesterol-lowering therapy, cardiovascular effects of diabetes therapies, and secondary prevention of CAD.

Benjamin Scirica, MD, MPH

Benjamin Scirica, MD, MPH graduated from Harvard Medical School and trained in internal medicine and cardiovascular medicine at Brigham and Women's Hospital in Boston, Massachusetts. He has a Master of Public Health degree from Harvard School of Public Health. He is currently Associate Professor of Medicine at Harvard Medical School and Senior Investigator at the TIMI Study Group. He is Director of Innovation in the cardiovascular division at Brigham and Women's Hospital.

His research interests center on the identification and application of novel cardiac biomarkers and therapeutic strategies across the spectrum of cardiometabolic disease. He was principal investigator of the AVANT GARDE-TIMI 43 trial and CAMELLIA-TIMI 61 and co-investigator of the MERLIN-TIMI 36, TRA 2Pº-TIMI 50, and SAVOR-TIMI 53 trials. He is the Director of the TIMI ECG Core Laboratory, which has analyzed over 20,000 continuous and static ECGs from multiple trials in acute coronary syndromes.

 Dr. Scirica has authored or co-authored over 100 peer-reviewed articles, serves on the editorial board of ACCEL, and is a reviewer for multiple journals, including The Lancet, Circulation and Journal of the American College of Cardiology (JACC). He practices in the Levine Cardiac Intensive Care Unit, cardiology in-patient service, and the Watkins Cardiovascular Clinic at Brigham and Women’s Hospital.

Back to top